Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Agenus

Aphria

Atreca

Bicycle Therapeutics Plc - ADR

Bristol-Myers

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals Inc

Amicus Therapeutics

GW Pharmaceuticals

OrganiGram Holdings Inc.

Pfizer

Sarepta Therapeutics

The coronavirus induced sell-off has created a number of attractive buying opportunities.

These 14 Stocks Are Stupid Cheap

Abeona Therapeutics

Avadel Pharma

Can these high-flying biotech stocks keep up their sizzling momentum?

3 Biotech Stocks That Soared This Week: Are They Buys?

CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 21,738 shares of RCUS on 06/06/2019 at an average price of $7.93 a share.

Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $172,382 of Shares

CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 41,540 shares of RCUS on 06/04/2019 at an average price of $7.91 a share.

Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $328,581 of Shares

Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results

Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?

ARCUS gene editing platform may be more specific and have less off-target side effects than CRISPR/Cas9.

Precision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T Platform

As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).

Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue? 

News for Arcus Biosciences Stock (RCUS)